Production of Lu-177 Radionuclide using Deuteron Beams: Comparison between (d,n) and (d,p) Nuclear Reactions

Kambali, Imam

doi:10.1088/1742-6596/1120/1/012011

Cited by 7 publications

(7 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…177 Lu can be routinely produced in high activity levels with a high specific activity in a nuclear reactor available worldwide 70 . Although 177 Lu can be crafted in a particle-accelerating machine or cyclotron 71 , nuclear reactor production via neutron activation is preferred. Two methods for 177 Lu production via a nuclear reactor are available, including a direct method and an indirect method 72 .…”

Section: Radiolabeled Psmamentioning

confidence: 99%

Lutetium-177-Labeled Prostate-Specific Membrane Antigen-617 for Molecular Imaging and Targeted Radioligand Therapy of Prostate Cancer

Ritawidya¹,

Wongso²,

Effendi³

et al. 2023

Adv Pharm Bull

View full text Add to dashboard Cite

Prostate-specific membrane antigen (PSMA) represents a promising target for PSMA-overexpressing diseases, especially prostate cancer-a common type of cancer among men worldwide. In response to the challenges in tackling prostate cancers, several promising PSMA inhibitors from a variety of molecular scaffolds (e.g., phosphorous-, thiol-, and urea-based molecules) have been developed. In addition, PSMA inhibitors bearing macrocyclic chelators have attracted interest due to their favorable pharmacokinetic properties. Recently, conjugating a small PSMA molecule inhibitor-bearing 1,4,7,10-N,N,N’’,N’’’-1,4,7,10-tetraacetic acid (DOTA) chelator, as exemplified by [177Lu]Lu-DOTA-PSMA-617 could serve as a molecular imaging probe and targeted radioligand therapy of metastatic-castration resistant prostate cancer (mCRPC). Hence, studies related to mCRPC have drawn global attention. In this review, the recent development of PSMA ligand-617-labeled with 177Lu for the management of mCRPC is presented. Its molecular mechanism of action, safety, efficacy, and future direction are also described.

show abstract

Section: Radiolabeled Psmamentioning

confidence: 99%

Lutetium-177-Labeled Prostate-Specific Membrane Antigen-617 for Molecular Imaging and Targeted Radioligand Therapy of Prostate Cancer

Ritawidya¹,

Wongso²,

Effendi³

et al. 2023

Adv Pharm Bull

View full text Add to dashboard Cite

show abstract

“…The behavior of the 11 MeV proton as it passes through the Havar window and in the enriched H2 18 O target was simulated using the Stopping and Range of Ions in Matter (SRIM) 2013 codes (Ziegler et al, 2010), whereas the energy of possible atomic impurities recoiled off the Havar window was examined using both the SRIM 2013 calculated data and the atomic collision equation, which has also been applied in deuterium and hydrogen adsorption studies (Kambali et al, 2008;Gladys et al, 2010;Kambali et al, 2018a;Kambali et al, 2018b;Kambali et al, 2018c). Moreover, collisions between recoiled off cobalt atoms and the silver (Ag) body housing the enriched water target were also simulated to study the origins of the impurities found in the post-irradiated enriched water target.…”

Section: Recoiling and Sputtering Calculationsmentioning

confidence: 99%

Recoiled and Sputtered Radioactive Impurities in 11 MeV Proton-based F-18 Production

Kambali¹,

Suryanto²,

Parwanto³

et al. 2019

IJTech

View full text Add to dashboard Cite

One of the quality control measures in F-18 radionuclide production concerns the impurities which might be present in the proton-irradiated enriched H2 18 O target. In this investigation, proton irradiations of enriched water targets were theoretically simulated by the Stopping and Range of Ions in Matter (SRIM) 2013 codes, followed by experimental measurements. First, the SRIM-calculated data were employed to understand the origins of the recoiled and sputtered species. Using a portable Gamma Ray Spectroscopy System, recoiled and sputtered radioactive impurities were measured in the enriched water target following F-18 production using 11 MeV proton beams. The experimental results indicate that Havar window-originated Co-56 radionuclide and silver body-originated Ag-110m radioisotope were identified in the postirradiated enriched H2 18 O target. In addition, after passing the 18 F solution through a column containing Quaternary Methyl Acetate (QMA) resin, none of the radionuclidic impurities were any longer observed to any great extent in the sample.

show abstract

“…In addition, it has a gamma photon that allows imaging of its bio-distribution in patients. This allows a more accurate estimate of target and critical organ dosimetry [10,11].…”

Section: Introductionmentioning

confidence: 99%

Kenya’s Proposed Research Reactor: Leveraging Nuclear Technologies for Sustainable Healthcare

Ochieng

Mpakany²

2023

Arab Journal of Nuclear Sciences and Applications

View full text Add to dashboard Cite

The government of Kenya recognizes the importance of research and development in realizing the country's vision in economic development and quality of life. Research reactors will be key in Kenya's medium-and long-term development plans in areas of research, industry, healthcare, education and training. Nuclear Power and Energy Agency, in collaboration with key stakeholders, is carrying out a feasibility study for the Kenya Nuclear Research Reactor (KNRR) project. The commissioning of the KNRR facility is projected for the year 2030. Radioisotope production has been identified as a priority utilization for the proposed RR facility to ensure self-sufficiency in production and availability of cost-effective radioisotopes for medical and other applications both for the country and the region. Further, the current and projected local and regional demand for radioisotopes for medical applications have been quantified. The prioritized radioisotopes are Mo-99/Tc-99m, I-125, I-131, Ir-192 and Lu-177. Successful implementation of KNRR project will improve the quality of healthcare in the country.

show abstract

Production of Lu-177 Radionuclide using Deuteron Beams: Comparison between (d,n) and (d,p) Nuclear Reactions

Cited by 7 publications

References 39 publications

Lutetium-177-Labeled Prostate-Specific Membrane Antigen-617 for Molecular Imaging and Targeted Radioligand Therapy of Prostate Cancer

Lutetium-177-Labeled Prostate-Specific Membrane Antigen-617 for Molecular Imaging and Targeted Radioligand Therapy of Prostate Cancer

Recoiled and Sputtered Radioactive Impurities in 11 MeV Proton-based F-18 Production

Kenya’s Proposed Research Reactor: Leveraging Nuclear Technologies for Sustainable Healthcare

Contact Info

Product

Resources

About